NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $3.54 -0.03 (-0.90%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Contineum Therapeutics Stock (NASDAQ:CTNM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Contineum Therapeutics alerts:Sign Up Key Stats Today's Range$3.51▼$3.6050-Day Range$3.51▼$7.9152-Week Range$3.43▼$22.00Volume72,428 shsAverage Volume81,690 shsMarket Capitalization$91.54 millionP/E RatioN/ADividend YieldN/APrice Target$22.50Consensus RatingBuy Company OverviewContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More… Contineum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCTNM MarketRank™: Contineum Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 591st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingContineum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContineum Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Contineum Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Contineum Therapeutics are expected to grow in the coming year, from ($2.01) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Contineum Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Contineum Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Contineum Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.28% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Contineum Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.28% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Contineum Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.07 News SentimentContineum Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Contineum Therapeutics this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of Contineum Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Contineum Therapeutics' insider trading history. Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTNM Stock News HeadlinesMorgan Stanley Lowers Contineum Therapeutics (NASDAQ:CTNM) Price Target to $20.00May 21, 2025 | americanbankingnews.comContineum Therapeutics' (CTNM) "Outperform" Rating Reiterated at Royal Bank of CanadaMay 18, 2025 | americanbankingnews.comF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.May 28, 2025 | The Tomorrow Investor (Ad)Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 15, 2025 | businesswire.comContineum Therapeutics Reports Q1 2025 Financial ResultsMay 15, 2025 | tipranks.comContineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesMay 14, 2025 | businesswire.comContineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of DevelopmentApril 30, 2025 | finance.yahoo.comWe're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn RateApril 23, 2025 | finance.yahoo.comSee More Headlines CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $14.65 at the start of the year. Since then, CTNM shares have decreased by 76.0% and is now trading at $3.51. View the best growth stocks for 2025 here. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) released its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.06. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00 per share. Who are Contineum Therapeutics' major shareholders? Contineum Therapeutics' top institutional investors include Altium Capital Management LLC (1.17%), ADAR1 Capital Management LLC (0.65%), Charles Schwab Investment Management Inc. (0.20%) and Dynamic Technology Lab Private Ltd (0.07%). How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Contineum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Contineum Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/14/2025Today5/27/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$31.00 Low Stock Price Target$16.00 Potential Upside/Downside+541.0%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$22.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.92% Return on Assets-20.52% Debt Debt-to-Equity RatioN/A Current Ratio37.06 Quick Ratio37.06 Sales & Book Value Annual Sales$50 million Price / Sales1.82 Cash Flow$0.55 per share Price / Cash Flow6.35 Book Value($3.72) per share Price / Book-0.94Miscellaneous Outstanding Shares25,872,000Free FloatN/AMarket Cap$90.81 million OptionableN/A BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CTNM) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.